Bradmer Pharmaceuticals Inc. (TSE:GLX) Given Average Recommendation of “Buy” by Analysts

Bradmer Pharmaceuticals Inc. (TSE:GLX) has earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, one has given a buy rating and four have given a strong buy rating to the company.

GLX has been the subject of a number of recent research reports. ATB Cormark Capital Markets cut shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Citigroup raised shares of Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. Finally, Chardan Capital raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th.

Bradmer Pharmaceuticals Price Performance